-
1 Comment
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.2.
Based on the above factors, ReShape Lifesciences Inc gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Medical Devices |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US76090R1014 |
| Market Cap | 5M |
|---|---|
| PE Ratio | None |
| Target Price | 1 |
| Beta | 2.12 |
| Dividend Yield | None |
ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in Irvine, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for RSLS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
